Does Gilead use non-GAAP financial measures, and why?

Yes, Gilead uses non-GAAP financial measures. Management believes these measures help in gaining a better understanding of the company's comparative operating performance and are useful for investors, by excluding items they deem unusual due to their nature, size, and infrequency.

Were there any significant non-GAAP adjustments in the second quarter of 2005?

No, according to the filing, there were no non-GAAP adjustments made for the second quarter of 2005, nor for the second quarter of 2004. This indicates that the reported GAAP results for these periods were considered representative of core operations by management.

What was the specific non-GAAP adjustment mentioned for a prior period?

The filing notes that for the first quarter of 2004, Gilead excluded a $20.6 million fair value gain and its related tax effects on Eyetech Pharmaceuticals, Inc. warrants. This exclusion was made because Eyetech had completed an initial public offering, and management felt excluding this event provided a clearer insight into the core business results and trends.

GILD 8-K: Earnings & Results

Q: What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to publicly announce Gilead Sciences, Inc.'s financial results for the second quarter ended June 30, 2005, and to provide investors with access to the detailed earnings press release.

Summary

Gilead Sciences, Inc. (GILD) filed an 8-K report on July 19, 2005, to announce its financial results for the second quarter ended June 30, 2005. The report primarily directs investors to a press release (Exhibit 99.1) containing these details. Management utilizes non-GAAP financial measures to provide a clearer view of the company's operating performance, though for the second quarters of 2005 and 2004, no such adjustments were deemed necessary. The company highlights that for the first quarter of 2004, a significant fair value gain related to Eyetech Pharmaceuticals, Inc. warrants was excluded from their non-GAAP reporting to better reflect core business trends. This filing emphasizes transparency in financial reporting and the management's perspective on understanding the company's ongoing operational performance.

Key Highlights

1Gilead Sciences announced its second quarter 2005 financial results via an 8-K filing on July 19, 2005.
2The primary information source for investors is a press release (Exhibit 99.1) attached to the filing.
3The company employs non-GAAP financial measures to enhance understanding of its comparative operating performance.
4Management believes non-GAAP measures are useful for investors in assessing core business trends.
5For the second quarters of 2005 and 2004, no non-GAAP adjustments were reported.
6A specific non-GAAP exclusion was made for the first quarter of 2004, related to a fair value gain on Eyetech Pharmaceuticals warrants, to isolate core business performance.
7The filing clarifies that the information herein and attached is not considered 'filed' for Section 18 liability purposes.

GILEAD SCIENCES, INC. 8-K Report, Financial Results (Jul 19, 2005)

Summary

Key Highlights

Frequently Asked Questions